Stable for up to 28 days af er reconstitutio

n

Power withControl

Fertipig®

Both gonadotrophins FSH and LH are important in the early phase afer weaning for the correct selection and growth of the pre-ovulatory follicles, which will finally ovulate afer the LH surge

<<

<<

Power with ControlFertipig®

Meet breeding targets

Weaned sows failing to return to oestrus within 7 days after weaning contribute to missed breeding targets and increased non-productive days (NPD).1 Longer lapse between weaning and oestrus together with real anoestrus contribute to the inability to completely fill vacant farrowing places and increased NPD costs.

The proper use of hCG+eCG allows you to meet your breeding targets and reduce NPD on farm

Parity (especially first parity), season, duration of lactation and energy balance can influence the duration of the weaning oestrus interval (WOI). The breeding target should be mimimum 95% of sows in heat within 5 days and inseminated within 7 days afer weaning. When those breeding targets are not being met, administration of eCG/hCG shortly after weaning can make the average WOI shorter.

Anoestrus after weaning may be observed particularly in the summer season, in primiparous sows or in cases of low energy balance.An effective strategy during the periods when anoestrus is likely to occur is to treat all sows at weaning with eCG/hCG combination.3

Individual treatment of sows not in heat within 7 days post weaning may result in fertile oestrus.4

The combination of 400IU eCG and 200IU of hCG mimics the action of FSH and LH when administered early after weaning and is able to induce a fertile oestrus with strong behavioural presence of heat in sows treated at weaning or in sows with anoestrus.

Fertile oestrusClearly visibleHigh ovulation rate

FOLLICLE ATRESIA WEANING

OESTRADIOL

LHLHFSH

OVULATION

FOLLICLE DEVELOPMENT

The main goal of breeding herds is to consistently meet breeding targets.

Induce High Quality Oestrus

Prevent Anoestrus

Reduce WOI

“Adapted from Foxcroft 2002”2

Ceva Repro Range

Building on the knowledge of the oestrus cycle and breeding targets, treatment with Fertipig® may be implemented either in a preventive way to all weaned sows in the batch at the day of weaning, or selectively to sows which are not in heat within 7 days after weaning.

Induction and synchronisation of oestrus

Reduction of WOI in sows with late oestrus

Prevention of anoestrus

Lower WOI, better synchronisation of oestrus

Prevention of silent heat

Treatment of seasonal anoestrus

Throughout the year

Seasonal anoestrus

Breeding targets are not achieved

Breeding targets are not achieved

In summer

Sow not in heat>7 days post weaning

Average WOI < 7 days<7

When do we treat?Fertipig® USES

The Correct use of Fertipig®

Power with ControlFertipig®

The Ceva product combining 400IU of eCG and 200IU of hCG in the lyophilized form as lyophilisate.

Power with ControlFertipig®

All sows at weaning

Higher piglet index

Less non-productive days (NPD)Improved concentration at work

Higher insemination rate

All sows at weaning

All sows at weaning

Sow not in heat>7 days post weaning

All sows at weaningin summer season

Which animals? Goals

£

Ceva Repro Range

Fertipig® improves on farm performance

Superior reproductive performance when Fertipig® is used to induce and synchronise groups of sows vs competitor on a farm with low reproductive performances due to seasonal impact.6

Higher treatment rate of anoestrus in sows vs competitor

Fertipig® treated sows had the tendency (p<0.1)to higher pregnancy and the farrowing rate as well as to bigger litter size.

Sows that did not exhibit signs of oestrus within 7 days after weaning were treated with Fertipig® (123 sows) within the period of 7-12 days after weaning or with product “G” (which contains PMSG and HCG) routinely used in the farms previously (113 sows).7

* However the difference were not statistically significant (p>0.05)

Comparison of pregnancy and farrowing rate

Pregnancy %

Farrowing %

79.50%80%

75%

70%

65%

60%

FERTIPIG® PRODUCT “P”

76.80%

72.40%

68.60%

Perc

ent

of p

regn

ancy

or

farr

owin

g

96% of sows treated with Fertipig® were in heat within 6 days afer weaning with the average weaning-to-insemination interval 4.08 days

<<

<<

<< Fertipig® treated sows had higher fertility*>>

Piglets total born

Piglets live born

Mean number of total born and live born piglets per group

13.9014

13,5

13

12,5

12

11,5

FERTIPIG® PRODUCT “P”

12.60

13.61

12.32

Num

ber

of p

igle

ts

57.760

50

40

30

20

10

0

OESTRUS RATE PREGNANCY RATE

52.8

42.5

FERTIPIG®

PRODUCT G

Perc

enta

ge fr

om th

e in

itia

l num

ber o

f sow

s

49.6

41.6

FARROWING RATE

Sows in heat within 7 days post treatment

100

95

90

85

80

FERTIPIG® CONTROL

INSEMINATION RATE

1400

1380

1360

1340

1320

1300

FERTIPIG® CONTROL

PIGLET INDEX

106

104

102

100

98

96

94

92

90

FERTIPIG® CONTROL

WOI

1

2

3

Better performance with Fertipig® by induction and synchronisation of oestrus.5

Comparison of pregnancy and farrowing rates

PL (

Pigl

ets/

100

sow

s)

WEA

N -

Oes

trus

(in

h)

Inse

min

atio

n Ra

te (

in %

)

Data from Farm A in the study

49.6

Data from Farm A in the study Data from Farm A in the study

Power with ControlFertipig®

Better stability-easy use

Benefits of long stability-in-use

600

400

200

0

eCG hCG

IU/d

ose

T0

T+3 W

T+5 W

Stability of eCG and hCG in Fertipig®

While all competitors’ products must be used after the reconstitution immediately or within 12 hours, Fertipig® has proven stability of eCG and hCG activities and sterility for up to 4 weeks after reconstitution.8 <<Fertipig® uniquely has officially

approved stability for up to 28 days afer reconstitution, store in a refrigerator (2°C - 8°C)>>

Nº of sows to be treated

Competitor Fertipig®

Week 1

Week 2

Week 3

Week 4

5 ds1 1

5 ds 5 ds1

5 ds 5 ds1 1 1

5 ds1 1 1 1

7

11

9

13

Stable for up to 28 days afer reconstitution

Better drugs inventory managementUNIQUE PRODU

CT

How to plan the stock?

Only 1 presentationrequired to fit your needs!

POWER WITHOUT CONTROL LEADS TO WASTAGE

400

196

421.4

196

455

213.2

Data from Farm A in the study

STAB

LE FOR UP TO 28 DAYS

Reference List1 Patterson JL, et al. J Swine Health Prod. 2010;18(4):196–1992 Foxcroft, R.G. 2002, Seminar on “Optimizing Reproductive Efficiency” at the 35th AASV Annual Meeting, Iowa3 Almond G.W. et al. 2006. B.E. Diseases of swine, 9th edition, 113-1484 S.P. Franek,et al. Weaning on Selected Reproductive Indicators of the Sow, Acta Vet. Brno 2008, 77: 193-1985 Pabst T., Proceedings Trends in sow reproduction, 20116 Krejci R. et al. Proceedings IPVS 2012, 927 Krejci R. et al. Proceedings IPVS 2012, 938 Ceva- Internal data

Use medicines responsibly (www.noah.co.uk/responsible)

Further information is available from Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FBTel: 01494 781510 Email: cevauk@ceva.com www.ceva.co.uk

Power with ControlFertipig®

Induction and synchronisation of oestrus.

Reduction of WOI.

Easy planning ofpurchase and use.

Better drugs inventory management.

Unique stability with 28 days of use afer reconstitution.

L229

-021

5-25

0

Further information is available on the data sheet

CONTRAINDICATIONS: Do not administer to pregnant animals. Do not administer to animals with known hypersensitivity to the active substances or to any of the excipients. Do not administer to sows with follicular cysts. SPECIAL WARNINGS: Treatment during the primary luteinised phase or in the middle of the cycle may increase the risk of ovarian cysts development. Do not adjust the dose. Increased doses do not increase the efficacy of the product. SPECIAL PRECAUTIONS FOR USE IN ANIMALS: Do not inject into the subcutaneous fat. SPECIAL PRECAUTIONS TO BE TAKEN BY THE USER: Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after handling the product. The product can cause a slight skin irritation. When the product comes into contact with the skin, rinse immediately with plenty of water. Pregnant women, women intending to become pregnant or whose pregnancy status is unknown, should not use the product due to the risk of unintended self-injection. Studies in laboratory animals exhibited dose-dependent teratogenic effects after the administration of the combination HCG / PMSG. People with known hypersentivity to gonadotrophins should avoid contact with the product. ADVERSE REACTIONS: In rare cases anaphylactic shock is seen by repeated administration of PMSG and HCG, since PMSG and HCG are exogenous proteins for other species than equine and human and therefore can provoke an antigen-antibody reaction. In case of anaphylactic shock, appropriate treatment should be administered. The frequency of possible adverse reactions is defined using the following convention: very common (affects more than 1 animal in 10) common (affects 1 to 10 animals in 100) uncommon (affects 1 to 10 animals in 1,000) rare (affects 1 to 10 animals in 10,000) very rare (affects less than 1 animals in 10,000) not known (frequency cannot be estimated from the available data). USE DURING PREGANCY, LACTATION & LAY: Do not administer to pregnant animals. Laboratory studies in laboratory animals have shown evidence of teratogenic effects after combined use of PMSG and HCG. INTERACTION WITH OTHER MEDICAL PRODUCTS: None known. AMOUNT(S) TO BE ADMINISTERED AND ADMINISTRATION ROUTE: Intramuscular use. Dissolve the lyophilisate with a small quantity of solvent. Mix to obtain a homogenous solution. Transfer this solution into the vial that contains the rest of the solvent. Shake the vial well to obtain homogenous solution. 400 IU of equine serum gonadotrophin and 200 IU of chorionic gonadotrophin per animal, i.e. 5 ml of the reconstituted solution in one administration within 24 hours after the weaning. OVERDOSE (SYMPTOMS, EMERGENCY PROCEDURES, AND ANTIDOTES) IF NECESSARY: A transient increase in progesterone level was observed following administration of 3 times the recommended dose, following the first oestrus. An induration and a transient erythema have been observed at the injection site during the product administration with three times the therapeutic dose. The daily administration of the therapeutic dose during 12 consecutive days can lead to the occurrence of ovarian cysts. WITHDRAWAL PERIOD: Meat and offal: zero days. LEGAL CATEGORY: UK POM-V IE POM MARKETING AUTHORISATION: Vm 15052/4050

SPECIES ADMINISTRATION ROUTE DOSAGE

Pigs (Sows) IM 5ml once after weaning